| Regulation FD Disclosure On October 30, 2026, the Board of Directors of Insulet Corporation (the “Company”) authorized a stock repurchase program, pursuant to which the Company may purchase up to $1 billion of its outstanding common stock through December 31, 2028. The Company plans to allocate approximately $400 million of this program toward repurchases in the fourth quarter of 2026, using existing cash. Under the stock repurchase program, the Company may repurchase its common stock from…

of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under

Entry into a Material Definitive Agreement. On September 21, 2026, Insulet Corporation (the “ Company ”) entered into the Ninth Amendment to Credit Agreement (the “ Amendment ”) with the lenders and other parties thereto and Morgan Stanley Senior Funding, Inc., as administrative agent (the “ Agent ”), amending that certain Credit Agreement, dated as of May 4, 2021 (as previously amended, supplemented or modified, the “ Credit Agreement ”, and as amended by the Amendment, the “ Amended Credit…

The filing discloses the adoption of a nonqualified deferred compensation plan, which is a compensatory arrangement rather than a change in management personnel.

Director — Timothy J. Scannell: Two long-serving directors, including the Chairman, are stepping down for personal reasons (health and political candidacy) without any reported disagreement with the company.

of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Class II director — Jonathan J. Mazelsky: Appointment of Jonathan J. Mazelsky as a Class II director, effective July 1, 2026.

Regulation FD Disclosure On May 26, 2026, Insulet Corporation (the “Company”) issued a press release announcing a voluntary Medical Device Correction for specific lots of Omnipod® products due to a manufacturing issue identified through ongoing product monitoring. A copy of the press release is furnished herewith. This action is separate from the Company’s March 12, 2026 voluntary Medical Device Correction. The two actions involved different manufacturing processes, both of which were related…

of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Regulation FD Disclosure On March 12, 2026, Insulet Corporation (the “Company”) issued a press release regarding a voluntary medical device correction. A copy of the press release is furnished herewith as Exhibit 99.1. While it is too early to ascertain the exact cost of the voluntary medical device correction, the Company currently expects to incur up to $40 million of costs associated with this event, all in 2026. These costs will be excluded from adjusted results. Accordingly, Insulet is n…

Chief Financial Officer — Ana M. Chadwick: The CFO departed the company and entered into a severance agreement.

Changes in Registrant’s Certifying Accountant On December 15, 2025, the Audit Committee of the Board of Directors of the Company notified GT, the Company’s then independent registered public accounting firm, that the Audit Committee selected PwC as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026. GT was previously engaged to audit the Company’s consolidated financial statements for the fiscal year ending December 31, 2025. The…

Regulation FD Disclosure On February 13, 2026, the Board of Directors of Insulet Corporation (the “Company”) approved a $350 million increase in the previously authorized $125 million stock repurchase authorization and extended the authorization through December 31, 2027. With this additional authorization, the total authorization for the repurchase program allows for the purchase of up to $475 million in shares of the Company’s common stock. As of February 16, 2026, the Company has repurchas…

of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Entry into a Material Definitive Agreement. On January 29, 2026, Insulet Corporation (the “ Company ”) and NXP USA, Inc. (“ NXP ”) entered into an Addendum effective January 1, 2026 (the “ 2026 Addendum”) to the Purchase Agreement, dated as of October 12, 2017, between the Company and NXP (the “ Original Agreement ”), as amended. Pursuant to the 2026 Addendum, the term of the Original Agreement, as amended, is extended, and certain terms and conditions related to pricing, product volume, prod…

of Form 8-K of Insulet Corporation dated December 15, 2025, and agree with the statements concerning our Firm contained therein. Very truly yours, GRANT THORNTON LLP 53 State Street, 16th Floor Boston, MA 02109 D +1 617 723 7900 F +1 617 723 6340

The filing pertains to the approval of amended and restated compensatory arrangements, not a management change.

of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Director — Robbie Huffines: Appointment of Robbie Huffines as a Class II director and member of the Audit Committee.

Chief Financial Officer — Flavia H. Pease: Ms. Chadwick is departing and being succeeded by Ms. Pease, an external hire.

of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Other Events. On June 9, 2025, the Company issued a notice of redemption (the “ Redemption Notice ”) for all of its outstanding 0.375% Convertible Senior Notes due 2026 (the “ Convertible Notes ” and the redemption thereof, the “ Redemption ”). Pursuant to the Redemption Notice, on August 20, 2025 (the “ Redemption Date ”), the Company will redeem any Convertible Notes that have not been converted, redeemed or repurchased prior to such date at a redemption price in cash equal to 100% of the p…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under

Entry into a Material Definitive Agreement. Credit Agreement Refinancing On June 6, 2025, Insulet Corporation (the “ Company ”) entered into the Eighth Amendment to Credit Agreement (the “ Amendment ”) with the lenders and other parties thereto and Morgan Stanley Senior Funding, Inc., as administrative agent (the “ Agent ”), amending that certain Credit Agreement, dated as of May 4, 2021 (as previously amended, supplemented or modified, the “ Credit Agreement ”, and as amended by the Amendmen…